Aslan Pharmaceuticals Ltd.
13F holders, Q1 2024 (March 31)22holders
3famous investors
$0.61avg. 13F price*
At the end of Q1 2024, 22 institutions reported holding Aslan Pharmaceuticals Ltd. in their 13F filings. The largest holders were BVF Inc. ($646K), Velan Capital Investment Management LP ($385K) and Shay Capital LLC ($246K). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Aslan Pharmaceuticals Ltd.
- CUSIP
- 04522R200
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $514K |
| Exits | 6 | $448K |
Ownership 22 holders
| BVF Inc. | 0.02% | No change | 1,049,999 | $646K |
| Velan Capital Investment Management LP | 0.21% | New | 625,000 | $385K |
| Shay Capital LLC | 0.07% | No change | 400,000 | $246K |
| Sio Capital Management, LLC | 0.05% | No change | 254,150 | $156K |
| Schonfeld Strategic Advisors LLC | 0.00% | Add +432.1% | 147,400 | $91K |
| Renaissance Technologies | 0.00% | Reduce -29.1% | 122,505 | $75K |
| Citadel Advisors | 0.00% | Reduce -80.0% | 96,604 | $59K |
| Marex Group Ltd | 0.00% | New | 83,364 | $51K |
| ADAR1 Capital Management, LLC | 0.01% | New | 59,393 | $37K |
| FNY Investment Advisers, LLC | 0.02% | New | 46,700 | $28K |
| Millennium Management | 0.00% | Reduce -50.7% | 39,641 | $24K |
| Walleye Capital LLC | 0.00% | New | 18,435 | $11K |
| Onyx Bridge Wealth Group LLC | 0.00% | No change | 22,727 | $9K |
| Waterfront Wealth Inc. | 0.00% | Reduce -49.4% | 20,722 | $9K |
| XTX Topco Ltd | 0.00% | Reduce -55.4% | 12,344 | $8K |
| Ikarian Capital, LLC | 0.00% | No change | 35,420 | $6K |
| Morgan Stanley | 0.00% | Reduce -64.8% | 8,700 | $5K |
| Bank of America Corp. | 0.00% | New | 3,036 | $2K |
| Capital Analysts, LLC | 0.00% | No change | 2,039 | $1K |
| Rhumbline Advisers | 0.00% | No change | 1,294 | $794 |
| Qube Research & Technologies Ltd | 0.00% | Reduce -85.5% | 34 | $21 |
| Cutler Group LLC / CA | 0.00% | Reduce -10.0% | 900 | $0 |
"% of holder's portfolio" is ASLAN PHARMACEUTICALS LTD's weight in each manager's 13F, not the share of Aslan Pharmaceuticals Ltd. the manager owns.